German pharma rebates fund health insurer surplus, but drug spending rises again
This article was originally published in Scrip
German health insurers enjoyed a €4 billion surplus in 2011, fuelled partly by a 4% drop in drug spending, which was in turn driven by increased mandatory rebates and a price freeze introduced in 2010. Although drug spending in Germany appears to be rising again, pharmaceutical companies will be calling for the government to reduce rebates to previous levels, says the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE).
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.